Do you want to receive the latest myeloma news and research for free, directly in your email inbox? You can with the Myeloma Minute!

Subscribe below to receive weekly email newsletters with up-to-the 'minute' information about multiple myeloma. The Myeloma Minute includes:

  • blogs and videos from Dr. Brian G.M. Durie,
  • inspirational videos,
  • information about drug recalls,
  • research announcements,
  • patient support events,
  • regional educational outreach,
  • advocacy action, and more.
Stay in Touch for the Latest Information
For late breaking news and events, subscribe to the Myeloma Minute!
The May 17, 2018 issue covers abstracts for the studies to be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting. Also discussed is an IMF study conducted in partnership with AbbVie examining the role of genetic mutation in outcomes of myeloma patients.
In the May 5, 2018 issue, Dr. Brian G.M. Durie, IMF Chairman of the Board, comments about the prevalence of multiple myeloma in the Asia-Pacific region. Also covered is the FDA approval of a fifth indication for Darzelex (daratumuab).
The May 3, 2018 issue covers how firefighters who responded to the World Trade Center terrorist attack are twice as likely to develop the myeloma precursor state MGUS. Also covered are patient stories, Mother's Day, and more.
The April 26, 2018 issue covers a new population-based study in the U.S. that follows in the footsteps of the IMF's iStopMM project in Iceland, as well as the approval of Darzalex in Sweden, and more.
The April 19, 2018 issue covers volunteer fundraisers, the 10th annual Miles for Myeloma, an IMF Patient and Family Seminar in Portugal, and more.
The April 12, 2018 issue covers the FDA fast track designation of selinexor for myeloma patients, the Black Swan researchers identify good-risk and poor-risk MRD patients, China’s ‘disruptive’ biotech, and reasons to eat ‘real food.'

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.